SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Exelixis, Inc. Licenses Two Drug Programs To Bristol-Myers Squibb Company; Exelixis Nabs $60M Upfront, Potentially $505M More